Hannah Joseph Hospital IPO Overview
Hannah Joseph Hospital Limited, a Madurai (Tamil Nadu) based multi‑specialty tertiary care healthcare provider, has launched its Initial Public Offering (IPO) to raise ₹42.00 crore entirely through a fresh issue of equity shares. The offer is priced in the ₹67 – ₹70 per share band and is being listed on the BSE SME platform. This issue is aimed at strengthening clinical offerings and expanding infrastructure at the hospital, particularly through the establishment of a radiation oncology centre.
Hannah Joseph Hospital operates a 150‑bed, NABH‑accredited multi‑specialty facility on a 2‑acre campus in Madurai, with core expertise in neurosciences, cardiology, psychiatry, trauma care and emergency services, supported by advanced clinical infrastructure and specialised departments.
IPO DETAILED INFORMATION
Issue Details
| Parameter | Details |
| IPO Type | BSE SME |
| IPO Open Date | 22 January 2026 (Thursday) |
| IPO Close Date | 27 January 2026 (Tuesday) |
| Allotment Date | 28 January 2026 (Expected) |
| Credit to Demat | 29 January 2026 (Expected) |
| Refund Initiation | 29 January 2026 (Expected) |
| Listing Date | 30 January 2026 (Tentative) |
| Price Band | ₹67 to ₹70 per share |
| Face Value | ₹10 per share |
| Lot Size | 2,000 shares |
| Min Investment (Retail) | ₹2,80,000 at upper band |
| sNII† Investment | ₹4,20,000+ (3 lots) |
| bNII Investment | Data not precisely disclosed publicly |
| Issue Size | ₹42.00 crore (Upper Band) |
| Fresh Issue | ₹42.00 crore (100% Fresh Issue) |
| Offer For Sale (OFS) | Nil |
| Total Shares Offered | 60,00,000 equity shares |
Issue Break‑up
| Category | Approx Allocation | Shares |
| Qualified Institutional Buyers (QIB) | ≤ ~47.43% | ~28,46,000 |
| Non‑Institutional Investors (NII) | ≥ ~14.30% | ~8,58,000 |
| Retail Individual Investors (RII) | ≥ ~33.27% | ~19,96,000 |
| Market Maker | ~5.00% | ~3,00,000 |
| Total | 100% | 60,00,000 |
Selling Shareholders (OFS)
NO OFFER FOR SALE — the entire IPO is a fresh issue of shares and no promoter selling is involved. All funds raised will go to the company for expansion and corporate purposes.
Objects of the Issue (Fund Utilization)
The net proceeds from the IPO are intended to be used primarily for:
- Capital Expenditure: Setting up a radiation oncology centre at the existing Madurai hospital campus.
- General Corporate Purposes: Supporting working capital requirements and other corporate needs.
The oncology centre project is a strategic investment to broaden the hospital’s service portfolio, enhance cancer care capabilities, and capture a larger share of specialised patient volumes.
Lead Managers & Registrar
- Book Running Lead Manager (BRLM): Capital Square Advisors Private Limited.
- Registrar to the Issue: Bigshare Services Private Limited.
Promoters & Management
Hannah Joseph Hospital is promoted by Dr. Mosesjoseph Arunkumar and Fenn Kavitha Fenn Arunkumar (names per draft prospectus), who are experienced healthcare professionals involved in the hospital’s operations and strategic direction.
COMPANY DETAILS
Hannah Joseph Hospital Limited was incorporated in October 2011 and later converted to a public limited company in July 2022. It operates a multi‑specialty tertiary care hospital in Madurai, Tamil Nadu, with a focus on high‑complexity treatments in neurosciences, cardiology, psychiatry, orthopaedics and trauma care. The hospital is supported by emergency and critical care infrastructure, modern diagnostic labs, operation theatres and specialised care units.
Key Service Areas:
- Neurosciences (Neurology & Neurosurgery)
- Cardiac Sciences (Cardiology & Cath Lab)
- Trauma & Orthopaedic Care
- Psychiatry & Mental Health Services
- Emergency & Critical Care
As of November 2025, the facility employed approximately 364 staff members across medical, clinical and support functions.
Company Strengths
- Established Multi‑Specialty Healthcare Facility: Recognised tertiary care hospital in South Tamil Nadu with strong service offerings.
- Advanced Clinical Capabilities: High‑value treatments in neurology, cardiology, trauma care and complex surgeries.
- Healthy Profitability: Consistent revenue growth and robust EBITDA margins above 26%.
- Strategic Expansion Investment: Oncology centre to broaden clinical services and enhance patient retention.
- Accreditations & Standards: NABH and other quality certifications reflect clinical governance and patient safety focus.
- Experienced Management: Promoter medical leadership with deep clinical and operational expertise.
- Strong Local Brand: Trusted hospital brand with decades of presence in the region.
Key Risks & Challenges
- SME Listing Volatility: SME IPOs often show significant price swings and lower liquidity post‑listing.
- High Retail Ticket Size: Minimum investment may deter smaller retail investors relative to some peers.
- Project Execution Uncertainty: Radiation oncology facility build‑out may face delays or regulatory hurdles.
- Healthcare Competition: Intense competition from larger hospital chains and local providers.
- Geographic Concentration: Operations concentrated in Tamil Nadu may limit pan‑India patient base.
- Funding Mix Risk: Reliance on external capital expenditures for expansion increases financial pressure.
Disclaimer
This document is for educational and informational purposes and does not constitute investment advice. Investors should read the Red Herring Prospectus (RHP) and consult certified financial advisors before making investment decisions. Past performance is not indicative of future results and investments are subject to market risks.
